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SUMMARY
Inflammatory cytokines and chemokines (CC) drive COVID-19 pathology. Yet, pa-
tients with similar circulating CC levels present with different disease severity.
Here, we determined 171 microRNAomes from 58 hospitalized COVID-19
patients (Cohort 1) and levels of 25 cytokines and chemokines (CC) in the same
samples. Combining microRNA (miRNA) and CC measurements allowed for
discrimination of severe cases with greater accuracy than using miRNA or CC
levels alone. Severity group-specific associations between miRNAs and COVID-
19-associated CC (e.g., IL6, CCL20) or clinical hallmarks of COVID-19 (e.g., neutro-
philia, hypoalbuminemia) separated patients with similar CC levels but different
disease severity. Analysis of an independent cohort of 108 patients from a
different center (Cohort 2) demonstrated feasibility of CC/miRNA profiling in
leftover hospital blood samples with similar severe disease CC and miRNA pro-
files, and revealed CCL20, IL6, IL10, and miR-451a as key correlates of fatal
COVID-19. These findings highlight that systemic miRNA/CC networks underpin
severe COVID-19.
INTRODUCTION
The COVID-19 pandemic has caused more than 5.2 million deaths (as of 1st December 2021,
https://coronavirus.jhu.edu). More than 263 million people have been infected with SARS-CoV-2, the
single-stranded RNA betacoronavirus that causes the disease. Infection results in a broad range of
outcomes, from asymptomatic infection to lethal pneumonia, acute respiratory distress syndrome, and im-
munothrombosis (Chen et al., 2020a, 2020b). Significant disease heterogeneity is observed even within
hospitalized individuals with COVID-19, with some requiring only management within a ward environment
andmodest supplemental oxygen support whereas others develop critical disease requiring invasive venti-
lation in intensive care units (ICUs). Age, comorbidities, host genetics, and the type of immune response
are all thought to play a decisive role in shaping the trajectory of the infection (Esai Selvan, 2020).
There is a precarious balance between protective immunity and immune-driven pathology in COVID-19,
with numerous studies identifying systemic and tissue correlates of severe and fatal disease. Systemic clin-
ical and immune correlates of severity include elevated CRP and D-dimer levels, increased numbers of neu-
trophils, lymphopenia, T cell exhaustion, increased number of proliferating plasmablasts and extrafollicular
B cell activation, and generation of platelet-sequestering nonclassical monocytes (Chen et al., 2020a; Diao
et al., 2020; Schulte-Schrepping et al., 2020; Terpos et al., 2020; Vanderbeke et al., 2021; Woodruff et al.,
2020; Wu et al., 2020). Consistent with the acute respiratory distress syndrome (ARDS) presentation of se-
vere COVID-19, multiple studies have also reported increased circulating levels of pro-inflammatory cyto-
kines and chemokines (CC) associated with COVID-19 severity including IL6, IL10, CCL2, CXCL10, and
GMCSF (COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium, 2021; Del Valle et al., 2020; Laing
et al., 2020; Mann et al., 2020; Thwaites et al., 2021; Zhao et al., 2020). Other CC, have also been reported
to predict severity, although less consistently (Chi et al., 2020; COvid-19 Multi-omics Blood ATlas (COM-
BAT) Consortium, 2021; Del Valle et al., 2020; Laing et al., 2020; Lucas et al., 2020; Zhao et al., 2020).
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However, it is notable that in the above studies a significant overlap in levels of COVID-19-associated CC is
observed between disease severity groups.
Circulating microRNAs (miRNAs) have been shown to be excellent disease diagnostic or prognostic
biomarkers in a wide range of chronic and acute inflammatory and infectious diseases including viral res-
piratory infection. Crucially, circulating miRNA levels are thought to reflect the state of the diseased tissue
(Correia et al., 2017; Sohel, 2020; Wittmann and Jack, 2010; Zeng et al., 2014). Despite their proven value as
mechanism-based clinical stratification indicators, miRNAs have only started being explored in the context
of COVID-19. It has been proposed that miRNAs might be involved in controlling inflammation during
COVID-19 (Aslani et al., 2021; Gasparello et al., 2021; Houshmandfar et al., 2021; Matarese et al., 2020;
Plowman and Lagos, 2021). Theoretical CC/miRNA regulatory networks have been proposed but not vali-
dated (Khokhar et al., 2022), whereas the potential of miRNA-like therapeutics has also been suggested
(Ahn et al., 2021; Dash et al., 2021; Hum et al., 2021; Park et al., 2021). Of note, initial studies have identified
potential changes in miRNA expression in COVID-19 and signatures from targeted testing of 41 miRNAs
have been linked to ICU treatment and mortality in a Spanish cohort (de Gonzalo-Calvo et al., 2021).
Furthermore, it has been reported that suppression of the hsa-miR-320 family is linked to COVID-19
severity (Duecker et al., 2021). Correlations between specific miRNAs and response to treatment (Sabba-
tinelli et al., 2021) or D-dimer levels and risk of thrombosis in COVID-19 patients have also been proposed
(Gambardella et al., 2021b). In addition, hsa-miR-2392 has been proposed both as a biomarker and ther-
apeutic target of SARS-CoV-2 infection (McDonald et al., 2021).
We hypothesized that combining measurements of circulating CC and miRNAs would reveal qualitative
changes associated with increased COVID-19 severity, leading to insight into determinants of COVID-19
outcome. We aimed to explore whether integrating miRNA with CC profiles would reveal a set of more ac-
curate correlates of COVID-19 severity and outcome, and to identify severity-specific correlations of
miRNAs with cytokine/chemokine and clinical parameter profiles in COVID-19. To achieve this, we
measured CC levels as potential initiators of pathogenic signaling and circulating miRNAs as indicators
of intracellular gene networks operating in combination with or in response to these CC. We first
performed cytokine, chemokine, and miRNA profiling in 171 blood plasma samples from 58 hospitalized
patients with mild, moderate, or severe COVID-19 (Cohort 1). We found that integrating clinical parameters
with systemic correlates of immune response and tissue status (cytokines, chemokines, and miRNAs)
revealed step changes occurring between clinical severity stages in COVID-19 and novel correlates of
severe COVID-19. These severity group-specific qualitative features of COVID-19 were unique to each
severity group and could only be observed by combiningmiRNA and CC profiling. Based on these findings,
we analyzed 166 samples from a second cohort of 108 hospitalized individuals using blood samples that
were leftover (or waste) from routine clinical testing following hospital admission (Cohort 2). Critically,
we were able to detect CC and miRNAs in these samples with similar severe-disease associated factors.
In this cohort, we were also able to search for principal systemic correlates of outcome (death or discharge).
Again, this revealed that combinations of CC with miRNAs (e.g., CCL20, IL6, IL10, hsa-miR-451a) were
better at predicting outcome than CC or miRNAs alone. Overall, our findings provide novel insight into
trajectories underpinning severe disease in symptomatic COVID-19 patients and support that integrating
miRNA and cytokine/chemokine profiling can shed light into determinants of disease severity as well as he-
matological and immunopathological features of COVID-19. Importantly, we demonstrate that miRNA/CC
measurements can be reliably performed in leftover blood samples that can be easily accessed in any
hospital setting.
RESULTS
Severe COVID-19 is linked to distinct plasma miRNA signatures
We performed circulating miRNA profiling as a nucleic-acid-based approach to discovering peripheral
correlates of disease in COVID-19 (Figure S1A). We analyzed samples from a first cohort (Cohort 1) of 58
hospitalized patients recruited between April and November 2020 in four hospitals in Manchester, UK as
part of the CIRCO cohort (Table S1) (Mann et al., 2020). These samples were collected for research pur-
poses. Patients were categorized in three groups of disease severity, mild (N = 20), moderate (N = 21),
and severe (N = 17), based on the requirement for respiratory support as described before (Mann et al.,
2020). Clinical measurements and comorbidity and symptom data were also available (Tables S2 and
S3). For several patients, follow-up plasma samples were analyzed, collected at different time-points
(typically taken every 1 to 2 days, Table S4).
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Expression ofmiRNAs was determined byNanostring profiling and 280miRNAs were detected in at least 10%
of the samples (see STAR Methods, Tables S5 and S6). First, we identified miRNAs that were differentially ex-
pressed in samples from individuals with severe disease vs the rest of the cohort (moderate andmild disease).
When all samples were included in the analysis (N = 171 samples) we identified 32 significantly differentially
expressed (DE) miRNAs (adjusted p <0.1; Figure 1A and Table S5). Downregulated miRNAs in severe disease
samples (25 in total, Table S5) included hsa-miR-323a-3p, hsa-miR-451a, hsa-miR-188-5p, and hsa-miR-432-5p,
whereas upregulated miRNAs (8 in total) included hsa-miR-4454 + 7975 (the mature sequence of hsa-miR-
7975 differs only by one base from hsa-miR-4454), hsa-miR-let-7a-5p, hsa-miR-let-7f-5p, hsa-miR-630, hsa-
miR-24-3p, and hsa-miR-29b-3p (Figure 1B and Table S5). We repeated the analysis including only the first
available sample for each patient (N = 58 samples). Although, differences in miRNA expression did not reach
significance after correcting for multiple testing, we identified six miRNAs which were DE in severe samples at
p <0.05 and absolute log2 fold change (absLFC) > 1 (Figures 1C and 1D and Table S5). These were hsa-
miR-4454 + 7975, hsa-miR-1285-5p, hsa-miR-320e, and hsa-miR-29b-3p, which were all upregulated, and
hsa-miR-451a and hsa-miR-144-3p, which were downregulated. hsa-miR-4454 + 7975, hsa-miR-29b-3p, and
hsa-miR-451a were identified in both analyses (including all samples or first samples). For these DE miRNAs,
we did not observe any significant changes in expression over the duration of hospitalization (not shown).
Having determined miRNA signatures associated with severe COVID-19 in hospitalized individuals, we per-
formed functional association analysis using the TAM 2.0 tool (Li et al., 2018). Using the list of DE expressed
miRNAs in severe cases (corresponding to Figure 1A), enriched functional terms for upregulated miRNAs
included cell death, innate immunity, and cell cycle (Figure 1E). For downregulated DE miRNAs, enriched
terms included Regulation of Stem Cell, Vascular inflammation, and Chemotaxis (Figure 1E). This indicated
terms that were likely to reflect the immune response to infection (e.g., innate immunity) but also terms
that could reflect tissue pathology (e.g., cell death). This was also the case, when performing functional
term enrichment analysis using the list of all DE miRNAs based on first available samples only (corresponding
to Figure 1B), with terms referring to wound healing and extracellular matrix remodeling being most enriched
(Figure S1B). We note that statistical significance was lower because of the smaller number of DEmiRNAs.We
then explored functional associations of top predicted targets of upregulated miRNAs in severe samples
using the Targetscan tool (Agarwal et al., 2015) (Figure S1C). Notably enriched gene ontology process asso-
ciations included terms involving extracellular matrix remodeling and responses to hypoxia consistent with
severe COVID-19 pathology (Figure 1F). Overall, our analyses revealed amiRNA signature associated with se-
vere COVID-19, which was reflective of tissue pathology and damage.
Progression from mild to moderate and severe COVID-19 is characterized by a global
reduction in circulating miRNA levels
Next, we explored miRNA signatures of mild COVID-19 disease within hospitalized individuals. When per-
forming comparisons, either including all samples or just first available samples, the most notable finding
was a decrease in circulating miRNA levels for the vast majority of detectable miRNAs in individuals with
severe and moderate disease when compared to individuals with mild disease (Figures 2A–2D). When
including all samples, mild cases were characterized by significantly higher levels (adjusted p <0.1) of
miRNAs including hsa-miR-495-3p, hsa-miR-150-5p, hsa-miR-432-5p, hsa-miR-376a-3p, hsa-miR-146a-5p,
and hsa-miR-451a (Figure 2B and Table S6). When including only the first available sample for each patient
differences were more modest (p <0.05, absLFC>1), and DE miRNAs included hsa-miR-548g-3p, hsa-miR-
150-5p, hsa-miR-590-5p, hsa-miR-518b, hsa-miR-363-3p, and hsa-miR-495-3p (Figures 2C and 2D, Table
S6). Functional association analysis, using TAM 2.0, indicated an enrichment in miRNAs contributing to im-
mune processes amongst DE miRNAs in mild COVID-19 (corresponding to Figure 2A), and more generic
cellular processes when considering only the first samples (Figure 2E). Exploring gene ontology terms
amongst the top predicted targets of upregulated miRNAs (Figure 2A), we observed enrichment in func-
tional terms associated with mRNA and small RNA metabolism (Figure 2F). This could reflect the type
response against SARS-CoV-2, a RNA virus. Alternatively, a change in RNAmetabolism, including process-
ing of small RNAs, could be associated with the higher circulating miRNA levels in patients with mild
disease. Overall, these analyses revealed a miRNA signature associated with mild COVID-19, reflecting
elements of both the immune response to SARS-CoV-2 infection but also tissue pathology.
Cytokine and chemokine profiling reveal quantitative and qualitative differences between
COVID-19 severity groups
In addition to miRNA profiling, we measured cytokine (Figures 3A and 3B) and chemokine (Figures 3C and
3D) levels in the same plasma samples. When including all samples as independent variables, we observed
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Figure 1. Plasma miRNA signatures of severe COVID-19
(A) Volcano plot comparing miRNA expression in severe against mild and moderate samples including all samples as
independent observations. Dotted lines correspond to log2 fold change (LFC) greater than one and Mann Whitney
p <0.05. Red dots correspond to miRNAs for which adjusted p <0.1 following Benjamini Hochberg (BH) correction.
(B) Violin plots of top DE expressed miRNAs in severe samples (adjusted p <0.1 and absolute LFC>1), including all
samples.
(C) Volcano plot comparing miRNA expression in severe against mild and moderate samples including only the first
available samples for each patient. Dotted lines correspond to log2 fold change (LFC) greater than one andMannWhitney
p <0.05.
(D) Violin plots of DE expressed miRNAs in severe samples when only the first sample per patient is included (p <0.05 and
absolute LFC>1).
(E) Significantly overrepresented functional terms within upregulated (shown in black) and downregulated (shown in gray)
miRNAs in severe cases (shown in red in (A)), including all samples as independent variables.
(F) Significantly overrepresented gene ontology process terms among predicted targets of miRNAs upregulated in
severe cases (red dots in the top right quadrant in (A).
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significant (adjusted p <0.05) upregulation of most tested cytokines in severe samples (Figure 3A and Table
S7). However, when taking only the first available samples for each patient only upregulation of IL-6 reached
statistical significance when comparing severe samples to moderate and mild (Figure 3B). With regards to
circulating chemokine levels, CCL3, CXCL9, CCL20, and CXCL1 were significantly upregulated in samples
from individuals with severe COVID-19 when compared against mild and moderate cases (Figure 3C).
Figure 2. Plasma miRNA signatures of mild COVID-19
(A) Volcano plot comparing miRNA expression in mild against moderate and severe samples including all samples as
independent observations. Dotted lines correspond to absolute LFC greater than one and Mann Whitney p <0.05. Red
dots correspond to miRNAs for which adjusted p <0.1 following BH correction.
(B) Violin plots of DE expressed miRNAs in mild samples (adjusted p <0.1), including all samples.
(C) Volcano plot comparing miRNA expression in mild against moderate and severe samples including only the first
available samples for each patient. Dotted lines correspond to absolute LFC greater than one andMannWhitney p < 0.05.
(D) Violin plots of DE expressed miRNAs in mild samples when only the first sample per patient is included (p <0.05 and
absolute LFC >1).
(E) Significantly overrepresented functional terms for miRNAs upregulated in mild samples when all samples (shown in
black) or only first samples (shown in gray) are analyzed.
(F) Significantly overrepresented gene ontology process terms among predicted targets of miRNAs upregulated in mild
cases (red dots in the top right quadrant in (A).
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Figure 3. Circulating cytokine and chemokine signatures of COVID-19
(A) Violin plots of measured cytokines in mild (green), moderate (blue), and severe (magenta) samples, including all
samples. Stars indicate significance for the comparison of severe against mild and moderate as follows: * adjusted
p <0.05, ** adjusted p <0.01, *** adjusted p <0.005.
(B) As in A, but analysis includes only first available samples per patient.
(C) As in A, but for circulating chemokines.
(D) As in C, but analysis includes only first available samples per patient.
(E) Heatmaps showing Spearman correlation between cytokines and chemokines for mild, moderate, and severe groups
separately. The average value over all available measurements for each patient was used in the calculation of correlations.
(F) Plots of IFNg against CCL20 levels in mild (green), moderate (blue), and severe (magenta) patients. Correlation
coefficients (c.c.) are shown above each scatter plot.
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Repeating the analysis to only include first samples, showed again increased levels of CXCL9 and CCL20 in
severe disease, but also increased levels of CXCL10 and a downregulation of CCL17 in patients with severe
COVID-19 (Figure 3D). Comparison of mild samples against the rest of the cohort (moderate and severe)
revealed significantly lower levels of CXCL9, CCL20, IL6, IL10, IFNg, and IL4 in mild samples, whereas levels
of CCL5 were significantly higher (Table S7). Within the studied sampling time frame we did not observe
any statistically significant patterns of regulation for DE CC over time (not shown).
We performed correlation analysis between individual CC, taking each sample as an independent obser-
vation (Figure S2A) or only including the first available sample for each patient (Figure S2B). However, we
also performed analyses using the average levels for each patient. This approach has the benefit of
capturing a representative and stable cytokine profile per patient, by including multiple sampling points
for most patients (Table S4) but avoiding overrepresentation of some patients because of a higher num-
ber of collected samples. The abovementioned lack of significant changes in CC levels over the studied
period meant that by taking an average of all measurements we were less likely to misrepresent the
levels of any specific protein in the correlation matrix. Following this approach, we found that IL2, IL4,
IL17A, IL17F, and TNF were positively correlated in all three severity groups (Figures 3E and S2C), as
were IL5 and IFNg but to a lesser extent particularly in the moderate group (Figures 3E, S2A, and
S2B). Notably, IL10 was also part of this correlation cluster but only for patients with mild disease.
Furthermore, CCL5 and CXCL1 were positively correlated in all groups. CXCL11 and CXCL5 were posi-
tively correlated with these, but only in mild and moderate disease groups respectively. CXCL10 and
CXCL9 also correlated in all groups, although the correlation was stronger in severe cases (Figure 3E
and S2D). IL9 was positively correlated with CCL3, CCL4, and CXCL8 in severe samples but to a lesser
extent, or not at all in moderate and mild samples, respectively (Figure 3E). CXCL1 and IL17F were nega-
tively correlated only in moderate and severe samples, the effect being stronger in severe. The same was
observed for CXCL10 and CCL17. Notably, we found a strong qualitative difference between the three
severity groups with regards to correlation between CCL20 and IFNg, which were not correlated in mild,
negatively correlated in moderate, and positively correlated in severe (Figure 3F). To identify relation-
ships between severity groups and high or low levels of cytokines or chemokines, we first performed cor-
respondence analysis with count data obtained by assigning values as low, medium, or high for each
severity group (see STAR Methods). This showed that, elevated IL6 (p <0.001), IL9 (p <0.05), IL10
(p <0.01), and CXCL1 (p <0.05) were significantly associated with the severe disease group, whereas
high values of CCL5 were associated with mild samples (Figure S2E). Overall, the CC profiling presented
here and correlation analyses per severity group demonstrated that in addition to quantitative, there
were also qualitative changes between severity groups.
Integration of miRNA and CC profiles reveals severity group-specific circulating molecular
signatures of COVID-19
To gain more insight into differences between severity groups we performed partial least squares regres-
sion (PLSR) analysis on the miRNA and CC profiles together (including all samples as independent obser-
vations). We found separation between samples from patients with severe disease and those with mild or
moderate disease (Figure 4A and S3A). Using PLS models, we performed leave-one-patient-out (L-O-P-O)
classification to assess the ability to predict severity based on our dataset. As discrimination between mild
and moderate samples was poor, we repeated the analysis with just two classes, severe vs mild/moderate.
The analysis was performed using only CC data, all miRNAs, only DE miRNAs, or CC data together with DE
miRNAs. We found that combining the CC levels with DE miRNAs resulted in the highest overall accuracy
(87%) in severity classification (Figure 4B).
To prevent individual patients with multiple samples dominating the analysis, we calculated correlations
using average values (one per patient). Notably, correlations between miRNAs and CC calculated across
the whole cohort were generally weak (Figure S3B). However, when performing the analysis within severity
groups stronger and distinct correlations were discovered (Figure S3C and Table S8). The number of these
correlations was notably higher in the severe disease group (Figure S3C, miRNAs and CC that show at least
one significant correlation with correlation coefficient higher than 0.4). We observed severity group-specific
features. CXCL1 showed positive correlations with a high number of miRNAs in severe disease compared
to mild and moderate. CXCL1 also clustered with CXCL9 and CXCL10 in samples with severe disease but
not in samples with moderate disease. IL6 showed several positive correlations with miRNAs and clustered
with IL10, CCL20, GMCSF, IL22, and IFNg in severe samples, and this was not the case for moderate and
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mild groups (with the exemption of CCL20). Interestingly, IL17F showed predominantly negative correla-
tions with miRNAs specifically in the severe disease group (Figure S3C). Strong, severity-group specific cor-
relations between CCL17 and miR-92a-3p (mild), CXCL1 and miR-1283 (moderate), IL-17F and miR-425-5p
(severe), and CXCL9 andmiR-1246 (severe) were also observed (Figure 4C). It is of note that, although these
correlations were severity group-specific, none of these miRNAs were significantly differentially expressed
in severe or mild samples (Tables S5 and S6).
Figure 4. Integration of miRNA, and cytokine and chemokine signatures
(A) Score plots for the first two latent variables from PLSR obtained using cytokine and chemokine data together with DE
miRNA measurements. The plot on the left was obtained using all three severity levels (mild, moderate, and severe),
whereas that on the right was obtained using only two classes (severe and mild/moderate).
(B) Results from PLSR with patients considered in two groups for different datasets with continuous output values
assigned to the nearest discrete class number. Accuracies shown were obtained using leave-one-patient-out cross
validation, using only cytokine and chemokine (CC) values, all miRNA values, only DEmiRNAs values, or combining all CC
values with DE miRNAs.
(C) Example scatterplots showing strong, severity group-specific correlations in mild (green), moderate (blue), or severe
(magenta) patients.
(D) Number of miRNAs (Y axis) in the top 5 strongest correlations with 1, 2, 3, 4, 5, 6, or over 6 cytokines/chemokines per
severity group. See Table S4
(E) Spearman correlation coefficients for top 5 correlated miRNAs with IL6 and CCL20 in mild (green), moderate (blue),
and severe (magenta) groups.
(F) As in E, but for CCL17, CXCL10, and CCL5.
(G) Canonical correlation analysis (CCA) to relate the miRNAs associated with cell death in the severe group (Figure 1E)
with cytokines and chemokines. Cytokines/chemokines with individual absolute correlation greater than 0.4 (for the
severe group) with any of these miRNAs were included in the analysis. The canonical scores plot shows data (from
individual samples) for the12 patients used to determine the canonical covariates (c.c. = 0.8, p = 4.8 3 106) in black. The
coefficients obtained are shown in the table and are used to obtain the canonical scores for 5 randomly chosen patients
reserved as an independent test set (plotted in red).
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Distinct miRNA correlates of CC expression underpin severe COVID-19
For differentially expressed CC in severe or mild samples we determined the five miRNAs with the
highest absolute correlation coefficients per severity group (Table S8). In addition to severity group-
specific top miRNA correlates of plasma CC levels, this analysis revealed a striking qualitative
difference for the severe group, namely the increased number of miRNAs featuring as top correlating
with multiple CC (Figure 4D). In severe patients, miR-30d-5p was in the top 5 most correlated miRNAs
for 9 CC. Furthermore, hsa-miR-425-5p and hsa-miR-19a-3p feature as top correlates of 8 CC, with
hsa-miR-19b-3p featuring a further 6 times (Table S8). There were no miRNAs in the top 5 lists of
more than 6 CC in mild or moderate cases. Conversely just 27 miRNAs appeared only once as one of
the top 5 strongest correlations in severe cases, the number increasing to 39 and 34 for moderate
and mild cases, respectively (Figure 4D). Of note, we observed distinct top correlating miRNA for
each severity group for all tested CC, including for example IL6 and CCL20, two cytokines strongly asso-
ciated with COVID-19 severity in our data (Figure 4E). In addition to different miRNAs, we found several
cytokines with opposing correlation trends. For example, all top strongest miRNA correlations for CCL17
were negative in the severe group but positive in the mild and moderate, the reverse being the case for
CXCL10. Similarly, the mild group was characterized by all top CCL5 correlations being negative in
contrast to moderate and severe groups (Figure 4F). Conversely, miRNAs showed group-specific
correlation patterns. For example, hsa-miR-24-3p, which was upregulated in patients with severe disease
in cohort 1 (Table S3), showed a negative correlation with TNF and IL4 in the severe cases group only
(Table S8).
Interestingly, the above cross-correlation analysis with miRNA expression (Figure S3C) separated in a
severity-dependent manner the IL2, IL4, IL17A, IL17F, TNF cluster found in Figure 3E (when only CC
expression was considered). This suggested that co-expression of these pro-inflammatory cytokines
might be associated with distinct immunological and/or tissue pathology effects in each subgroup.
We further explored this by focusing on miRNAs that contributed to enrichment of the cell death func-
tional association amongst DE miRNAs in severe samples (Figure 1E). These miRNAs were miR-24-3p,
Let-7f-5p, miR-630, miR-29b-3p, and Let-7a-5p. We reasoned that a set of chemokines or cytokines
that would correlate with these miRNAs as a group could potentially be primary candidates to be effec-
tors of lung tissue damage. We used canonical correlation analysis (CCA) to relate a linear combination
of the miRNAs associated with cell death with a linear combination of the CC that showed the highest
correlations individually with at least one of these miRNAs in severe samples (Table S9). The coefficients
in the linear combinations with maximal correlation, obtained using samples from only 12 of the 17 pa-
tients in the severe group, are given in Figure 4G. For this data, the correlation for this first canonical pair
was 0.8 (p = 4.79 3 106), identifying IL4 and TNF as the predominant contributors to the correlation with
cell death miRNAs, with minor contributions from IL17F, CCL3, IFNg, IL9, and IL10. We note here that
collinearity because of correlations within these CC may make individual contributions difficult to esti-
mate. Applying the coefficients to the data for samples from the remaining 5 severe patients showed
that the model generalizes to unseen data with the correlation over all severe samples being 0.76.
The canonical variates are plotted for both training and test data in Figure 4G. The above findings iden-
tified systemic signatures that were both quantitatively and qualitatively different between COVID-19
severity groups.
Integration of miRNA and CC profiles with clinical parameters in hospitalized COVID-19
patients
We then explored how these could potentially underpin clinical features of COVID-19 by correlating levels
of CC with clinical measurements. Clinical measurements were acquired only at the time of first blood sam-
pling, therefore for this analysis we used CC levels from the first available plasma sample for each
participant.
In severe samples, we found a cluster including IL6, IFNg, CCL2, and CCL20 positively correlating
with ALT, CRP, saturated O2, and creatinine and negatively correlating with HCT (Figure 5A). A
second cluster including TNF, IL17A, IL17F, IL9, IL2, and IL4 correlated positively with several cell
populations including neutrophils and eosinophils but largely negatively with monocytes and
lymphocytes. This clustering profile was specific to severe cases. Several strong and group-specific
correlations were observed. IL9 correlated positively and strongly with lymphocytes in moderate
cases, modestly in mild, and not at all in severe (Figure 5A). Other group-specific correlations included
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IL17F with BMI and CCL11 with temperature in mild, CCL11 with MCV and CXCL10 with WCC in mod-
erate, and CCL5 with potassium and CXCL9 with ALP in severe (Figure 5B). Interestingly, we noted
that cytokines widely associated with COVID-19 severity such IL6, CXCL10, and TNF showed multiple
Figure 5. Correlation analysis of cytokine and chemokine profiles with clinical parameters
(A) Heatmaps showing Spearman correlation coefficients (c.c.) between cytokines and chemokines and clinical
measurements for mild, moderate, and severe groups. The first cytokine/chemokine value was used for each patient.
(B) Example scatter plots for strong, severity group-specific correlations between cytokines/chemokines and clinical
parameters in mild (green), moderate (blue), or severe (magenta) patients. Correlation coefficients (c.c.) are also shown.
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but modest correlations with clinical parameters in all groups, likely reflecting their multifunctional role in
disease development.
We also investigated significant correlations between levels of individual miRNAs and clinical measure-
ments. The clinical parameters were separated in different clusters between groups and the number of
strong correlations (absolute value >0.4) was higher in moderate cases (Figures 6A–6C). Of note clinical pa-
rameters, previously associated with COVID-19 severity, separated in different clusters between groups.
For example, albumin and globulin (Feketea and Vlacha, 2020) clustered together in mild and moderate
samples but not in severe (Figures 6A–6C) and the top miRNA correlates of albumin and globulin were
distinct between severity groups (Figure 6D). In addition, the topmiRNA correlates of lymphocyte numbers
showed positive correlations in the moderate and severe groups but negative correlations in the mild,
while we also observed severity group-specific correlations between miRNAs and neutrophils (Figure 6D).
Interestingly, for CRP (Figure 6D) and hemoglobin (Figure S4), we found switches in the type of correlation
and identity of miRNAs between mild and moderate cases, whereas only modest correlations were
observed in the severe group (Figure 6C). Similar group-specific correlations were observed for all tested
clinical parameters (Figure S4). In all groups we observed multiple positive correlations between platelets
and individual miRNAs (Figure S4). However, we did not find anymiRNAs that correlated with platelets in all
groups. Eleven miRNAs strongly correlated with platelets in at least two groups. Overall, integration of
cytokine, chemokine, and miRNA profiles with clinical parameters identified commonalities but also signif-
icant differences between disease severity groups in hospitalized individuals.
Figure 6. Severity-specific correlations between miRNAs and COVID-19-associated clinical parameters
(A) Heatmap showing Spearman correlation coefficients (c.c.) between miRNAs and clinical measurements for the mild
group of patients. Values shown for miRNAs with absolute c.c. >0.6 with at least one clinical parameter. The first miRNA
value was used for each patient.
(B) As in A, but for moderate cases.
(C) As in A, but for severe cases.
(D) Spearman correlation coefficients for top 5 correlated miRNAs with indicated clinical parameters in mild (green),
moderate (blue), and severe (magenta) groups.
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Application of CC/miRNA profiling using leftover blood samples from routine clinical testing
highlights factors associated with fatal COVID-19
To test the potential for wider application of miRNA/CC profiling in clinical practice, we analyzed an indepen-
dent COVID-19 patient cohort including 166 leftover blood samples from 108 hospitalized individuals
(66 mild, 21 moderate, 21 severe) between January and March 2020 (cohort 2). These samples were collected
for clinical assessment and diagnostic purposes (e.g., complete blood counts). Importantly, samples had to
be stored at room temperature (typically 12–48 h) before plasma separation, to be available in case they
were required for further clinical tests. Samples were collected at admission for all patients, with somepatients
having follow-up samples (Table S10). In this cohort, wemeasured levels of miRNAs identified as differentially
expressed in cohort 1 by qRTPCR, including hsa-miR-4454 (we chose this over hsa-miR-7975 as it is more
abundant based on publicly available data in www.miRBase.org), hsa-miR-29b-3p, hsa-miR-451a, hsa-miR-
630, hsa-miR-146a-5p, hsa-miR-495-3p, hsa-miR-320e, and hsa-miR-144-3p. We also measured levels of
hsa-miR-21-5p as a control miRNA that did not show differential expression between groups in cohort 1
(Figures 1 and 2, and Tables S5 and S6). We opted to measure miRNA levels by qRTPCR as an orthogonal
technique to Nanostring profiling, appropriate for candidate miRNA measurement. Levels of all CC shown
in Figure 2 were also measured. Strikingly, despite storage of these samples at room temperature before
plasma isolation, we observed notable similarities in differential expression. As in cohort 1, levels of CCL2,
CCL20, IL6, IL9, IL10, IFNg, IL17A, IL17F, IL4, IL22, hsa-miR-4454, and miR-630 were significantly (adjusted
p <0.05) different in severe cases (Figures 7A–7C). It is of note that several cytokine and chemokine receptors
are predicted targets of the two miRNAs found to be associated with severe disease in both cohorts. Pre-
dicted hsa-miR-4454 targets include IL10, IL1R1, IL13RA1, IL18BP, IL10RB, and CCR4, and predicted hsa-
miR-630 targets include IL7, IL17D, IL23R, IL15RA, CCR4, CXCL13, CXCL14, CCR2, CCL11, and CCR5. We
observed similar core correlations between CC (i.e., correlations occurring in all groups) as in cohort 1,
including CXCL10 with CXCL9 (and CXCL11 in cohort 2), IL4, with IL71A, IL17F, and TNF (and IL2 to a lesser
extent), CXCL1 with CXCL5, and IL6 with IL10 and IL22 (Figures S5A–S5C). Similarly to cohort 1, CXCL10 and
CCL17 showed a negative correlation only in severe and moderate cases. We note that we did not observe a
strong correlation between CCL20 and IFNg in severe cases, although we still observed the strongest nega-
tive correlation between CCL20 and IFNg in moderate cases as was the case with cohort 1 (compare Fig-
ure S5B and 3F). We did not perform correlation analyses between miRNAs and CC, as we only measured
levels of 9 preselected miRNAs rather than the whole miRNome.
The higher number of patients in the cohort 2 allowed us to test CC and miRNA correlates of COVID-19
outcome (discharge or death). Twenty-four patients were deceased and 84 discharged (Table S10). We
found that fatal COVID-19 was associated with higher levels of IL6, IL10, IL22, CXCL10, CCL2, and
CCL20 and lower levels of miR-495-3p, miR-451a, and miR-29b-3p (Figures 7D–7F). To identify main sys-
temic correlates of fatality, we used forwards stepwise logistic regression to construct models connecting
miRNAs and CC with outcome. We started with a null model and allowed any of the variables found to be
statistically significant individually (Figures 7A–7F) to be added if the model improved. This resulted in a
model including CCL20, IL6, IL10, and hsa-miR-451a (Figures 7G and Table S11), which was compared to
a model with only CCL20 (the most statistically significantly associated factor with fatal COVID-19, adjusted
p = 1.02 3 109). Although classification accuracies were comparable between the two models, both the re-
sidual deviance (the lack of fit to the perfect model) and the Akaike information criterion (AIC; a measure of
prediction error) were smaller for this model, indicating that the CCL20/IL6/IL10/hsa-miR-451a model fitted
the data better and suggesting a potential role for these CC and miRNA in fatal COVID-19. A third model
that considered all variables without strong outliers (CXCL10, CCL17, CCL2, CCL3, CXCL9, CXCL5, CCL20,
CXCL11, CCL4, IL6, IL10, TNF, IL17F, IL22, hsa-miR-4454, hsa-miR-29b-3p, hsa-miR-451a, hsa-miR-630, hsa-
miR-146a-5p, hsa-miR-495-3p, and hsa-miR-144-3p) resulted in inclusion of 11 variables, including three
miRNAs: CCL17, CCL2, CXCL5, CCL20, IL6, IL10, IL17F, IL22, hsa-miR-4454, hsa-miR-495-3p, hsa-miR-
451a (Figures 7G and 7H, Table S11). This 3miRNA/11CC model showed the highest accuracy (79%–
90%) and lowest deviance (79.204) and AIC (103.2). Taken together, the second cohort analyses demon-
strated the feasibility of miRNA and CC profiling in leftover blood samples, identified CC and miRNAs
that were statistically elevated in severe cases in both cohorts, and allowed us to build a model highlighting
CC and miRNA correlates of fatal COVID-19.
DISCUSSION
Our study represents the largest circulating miRNA profiling study in COVID-19, including whole
miRNAome and multiplex CC analysis of 337 samples from 166 patients from 4 hospitals and two different
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Figure 7. miRNA/CC correlates of fatal COVID-19 identified in a leftover blood sample cohort
(A) Violin plots of measured cytokines in mild (green), moderate (blue), and severe (magenta) samples, in the leftover blood sample cohort. Stars indicate
significance for the comparison of severe against mild and moderate as follows: * adjusted p <0.05, ** adjusted p <0.01, *** adjusted p <0.005.
(B) As in A, but for chemokine levels.
(C) As in A, but for miRNA levels.
(D) Violin plots of measured cytokines in samples from discharged (white) and deceased (gray) patients, in the leftover blood sample cohort. Stars indicate
significance for the comparison of severe against mild and moderate as follows: * adjusted p <0.05, ** adjusted p <0.01, *** adjusted p <0.005.
(E) As in D, but for chemokine levels.
(F) As in D, but for miRNA levels.
(G) Results of forward regression models including accuracy for deceased and discharged patients, residual deviance, and AIC. Results are shown for the
CCL20-only model, the CCL20/IL6/IL10/miR-451a model, and the 3 miRNAs/11 CC models (see Table S11).
(H) Balloon plots for the parameters included in the 3 miRNAs/11 CC model. The size of each dot reflects the number of patients in the deceased or
discharged group with high (left panel), or low (right panel) levels of the shown CCs andmiRNAs. Gray blocks indicate the proportion of the total counts (high
or low) each variable accounts for. See STAR methods for definition of high and low values.
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geographical locations in the UK. Using miRNA profiling to deconvolute CC abundance resulted in iden-
tifying sets of miRNAs that correlate in a severity-specific manner with CC already associated with COVID-
19 severity such as IL6 and CXCL10 (Coperchini et al., 2021). Overall, we show that determining correlations
between miRNAs and these CC can robustly identify patients with severe disease in a manner not possible
through analysis of CC alone. Importantly, these miRNAs reflect intracellular gene networks (e.g., hypoxia,
apoptosis, etc) providing mechanistic insight into the context-dependent function of CC in severe COVID-
19. It is of note that several of the severity group-specific miRNA-CC or miRNA-clinical parameter correla-
tions we report involve miRNAs that are not significantly differentially expressed in severe or mild samples.
This indicates the emergence of disease-associated novel networks rather than just quantitative increase of
interactions operating in a continuum during progression from mild to moderate to severe disease. Inter-
estingly, although such qualitative changes are more numerous and profound when combining miRNA and
CC profiling, a small number can be already determined when exploring CC levels alone. In Cohort 1, IFNg
and CCL20 showed a strong positive correlation only in patients with severe disease. Of note, IFNg is an
essential trigger of antimicrobial pulmonary responses, but increased IFNg levels in COVID-19 blood
and airways samples are associated with pathogenesis and pulmonary tissue damage (Chua et al., 2020;
Karki et al., 2021; Montalvo Villalba et al., 2020), possibly through a detrimental effect of IFNg on epithelial
cells (Heuberger et al., 2021). On the other hand, CCL20 is secreted by the bronchial epithelium and impor-
tant for lung immunity, but it can lead to pathogenic responses (Ito et al., 2011). Therefore, the strongly
correlated IFNg and CCL20 may mark a circulating readout of severe respiratory disease complications.
Our approach can be used as a foundation for stratifying patients and understanding response to CC-tar-
geting treatments such as anti-IL6R blocking antibodies (Galvan-Roman et al., 2021). Indeed, small-scale
studies have proposed candidate miRNA predictors of response to IL6R blockade (Sabbatinelli et al.,
2021). In this respect, testing the applicability of our findings from Cohort 1 when analyzing leftover (or
waste) blood samples (Cohort 2), which are obtained in every hospital as part of routine care, has wide-
reaching implications in clinical practice. Identifying CC and miRNAs with altered levels in patients with
severe COVID-19 in both cohorts is notable, as in addition to significant differences in method and time
of sampling (e.g., immediate processing and freezing, Ficoll-based separation, collection within 1 to
2 days of admission for Cohort 1 vs storage at room temperature for 12 to 24 h, plasma isolation by centri-
fugation, and collection at hospital admission in Cohort 2), Cohort 1 was predominantly recruited during
the first wave of the pandemic but Cohort 2 was recruited during the second wave of the pandemic in
the UK. Therefore, commonalities between the two cohorts span different dominant SARS-CoV-2 variants
and changes in clinical practice that occurred between the first two waves of the pandemic. Differences
between the two cohorts should be interpreted cautiously as they can be a result of technical or
immune-virological differences between the two cohorts.
A correlation between circulating and diseased tissue profiles has been extensively reported in cancer,
and autoimmune and infectious diseases (Correia et al., 2017; Sohel, 2020; Wittmann and Jack, 2010;
Zeng et al., 2014). Our analyses in Cohort 1 show that both circulating miRNAs and their predicted tar-
gets are indeed reflective of processes occurring at the tissue level (e.g., cell death, response to hypoxia,
extracellular matrix remodeling). This provides a powerful tool in further understanding main activities of
multifunctional CC. For example, we identify a significant linkage between IL4 and TNF and cell death-
associated miRNAs, including hsa-miR-24-3p, which has previously been linked to cerebrovascular effects
(Gambardella et al., 2021a; Mone et al., 2021). These associations do not imply causality, as changes in
circulating CC levels can also be the consequence of tissue damage. Interestingly, hsa-miR-24-3p was
also proposed as a potential component of computationally predicted miRNA/CC regulatory networks
operating during COVID-19 (Khokhar et al., 2022), and was with hsa-miR-335-5p one of the only two
miRNAs from this study to be highlighted in our analyses. In addition, a smaller study compared 10
COVID-19 patients with 10 healthy controls and identified 55 DE miRNAs in COVID-19 patients (Farr
et al., 2021). Seven of these miRNAs (hsa-let-7a-5p, hsa-let-7f-5p, hsa-miR-150-5p, hsa-miR-423-5p,
hsa-miR-432-5p, hsa-miR-451a, hsa-miR-651-5p) were also found to be associated with severity in our
study, as they were DE in severe or mild patients. Another study reported down-regulation of hsa-
miR-320a,b,c family members when comparing 10 severe cases to 8 healthy controls (Duecker et al.,
2021), something we did not observe in our study. This discrepancy could be because of the small
size of the previous study, the fact that the previous study compared COVID-19 patients to healthy con-
trols using a different miRNA detection platform (Nanostring vs small RNA sequencing), or differential
expression of family members between cohorts.
ll
OPEN ACCESS
14 iScience 25, 103672, January 21, 2022
iScience
Article
A strength of our analysis in Cohort 1 was the ability to perform correlation analysis with clinical laboratory
measurements. In severe samples, two CC clusters were observed one of which (TNF, IL17A, IL17F, IL9, IL2,
and IL4) correlated positively with neutrophils and largely negatively with monocytes and lymphocytes,
providing insight into inflammatory profiles associated with lymphopenia and neutrophilia occurring in se-
vere COVID-19 (Henry et al., 2020; Terpos et al., 2020). Of note, several miRNAs correlate with platelets in
our analysis. Although we cannot exclude the possibility that this could be partly because of platelet
contamination or lysis, among a list of 11 miRNAs previously reported to strongly correlate with
platelet contamination (Mitchell et al., 2016) only two (hsa-miR-93-5p and hsa-miR-17-5p) correlated with
platelets in more than one severity group in our study. Alternatively, as platelet-secreted miRNAs reflect
platelet activation and function (Czajka et al., 2021), severity group-specific platelet-associated miRNA
signatures could provide novel insight into the observed thrombocytopenia and platelet aggregation
phenotype in severe COVID-19 (Lippi et al., 2020; Rampotas and Pavord, 2020).
Although Cohort 1 allowed us to perform unbiased miRNA and CC profiling in high-quality clinical
samples, its smaller size meant that it was not possible to attempt analyses of outcome. Cohort 2, however,
allowed us to perform this analysis. The two cohorts could not be merged because of the different meth-
odologies used to measure miRNA levels. Others have reported a link between elevated IL6 and IL10 levels
to fatality (Li et al., 2021) providing external validation of our data collected from leftover blood samples.
However, these factors alone are not sufficient for prediction of outcome (Liu et al., 2021b). Our study also
revealed CCL20 as a key correlate of fatal COVID-19. Increased circulating CCL20 levels in blood as well as
respiratory tract samples have been reported in severe COVID-19 patients and linked to ARDS (Chua et al.,
2020; Hue et al., 2020; Saris et al., 2021), but the profound link to fatal COVID-19 observed here is less
appreciated. Importantly, combining miRNA with CC profiling leads to improved and more accurate
models of correlates of fatal COVID-19 including hsa-miR-451a, hsa-miR-495-3p, and hsa-miR-4454. Of
note hsa-miR-451a was also linked to COVID-19 in the above-mentioned comparison of COVID-19 patients
to healthy controls (Farr et al., 2021). These findings provide a solid foundation for other studies further vali-
dating fatal COVID-19-associated CC and miRNAs.
Overall, we propose that integrated miRNA/CC profiling can determine key systemic changes that reflect
the step-wise progression of COVID-19. Other methodologies such as whole blood RNA sequencing, sin-
gle cell RNA sequencing, high-resolution proteomics, or autoantibody profiling also support the existence
of distinct disease progression trajectories characterized by unique quantitative and qualitative features
(Bergamaschi et al., 2021; Bost et al., 2020; Liu et al., 2021a; Stephenson et al., 2021; Wang et al., 2021).
Identifying qualitative differences between different COVID-19 severity manifestations and quantitative
correlates of potentially fatal disease in symptomatic individuals and investigating their mechanistic rele-
vance can provide important clues for development of future COVID-19 therapies. Using exclusively circu-
lating measurements and easy-to-obtain samples to dissect these differences means that our work already
provides a set of candidate biomarkers that can be used by the clinical and research community to study
pathogenesis and treatment of COVID-19. We propose that targeted tandem miRNA-CC profiling pro-
vides a flexible noninvasive toolkit to helpmechanistic studies, patient stratification, and response-to-treat-
ment monitoring for future and current COVID-19 therapeutics.
Limitations of the study
One limitation of our study is that its size does not allow us to perform extensive analysis of all possible
confounders (Tables S1 and S3) and risk analysis to identify independent predictors of COVID-19 severity
or outcome. As such future studies in independent cohorts will need to further validate our results. Another
limitation of our study is that only patients from the North of England were recruited. Although the severity-
associated CC profiles identified here do not significantly differ to those reported in previous studies
(COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium, 2021; Del Valle et al., 2020; Laing et al.,
2020; Mann et al., 2020; Thwaites et al., 2021; Zhao et al., 2020), this geographic limitation should be high-
lighted. In terms of other biases associated with observational cohort studies (Sedgwick, 2014), we note
that although the number of follow-up samples was not different between severity groups (Table S4),
the duration varied. To counter this bias, we performed some analyses including only the first available
sample or the mean value from all samples for each participant. Furthermore, although we cannot exclude
selection biases, such effects are likely to be reduced through including only hospitalized COVID-19 pa-
tients (all exposed and positive to SARS-CoV-2; no healthy controls) and studying two cohorts, one of which
recruited prospectively. Lastly, as all our measurements were taken from plasma the cellular source of
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detected CC and miRNAs is not known, therefore it is not possible to assess whether there are direct in-
teractions between the detected miRNAs and CC.
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Data and code availability
d Nanostring miRNA profiling data have been deposited at GEO and are publicly available as of the date
of publication. Accession numbers are listed in the key resources table.
d This study does not report original code
REAGENT or RESOURCE SOURCE IDENTIFIER
Biological samples
Plasma samples from COVID-19 hospitalised
patients (cohort 1)
Manchester hospitals under the
framework of the Manchester
Allergy, Respiratory and Thoracic
Surgery (ManARTS) and the
Northern Care Alliance Research
Collection (NCARC)
ManARTS Biobank (study no M2020-88,
ethics: 15/NW/0409);
NCARC tissue biobank (study no.
NCA-009; ethics 18/WA/0368).
Leftover hospital blood samples from hospitalised
COVID-19 patients (cohort 2)
York District Hospital, York and
Scarborough NHS Trust
REC reference 19/YH/0394 with
approved SA002 amendment of
IRAS project 269597
Critical commercial assays
LEGENDplex HU Th Cytokine Panel (12-plex) w/ VbP V02 BioLegend Cat #741028
LEGENDplex Human Proinflammatory chemokine Panel 1 BioLegend Cat #741081
LEGENDplex Human CCL5 1-plex BioLegend Cat #741083
GM-CSF ABTS ELISA kit Peprotech
Norgen Plasma/Serum RNA Purification Mini kit Norgen Cat #55000
miRNA Taqman assays Thermo Fischer Cat #4427975
Taqman MicroRNA Reverse Transcription Kit Thermo Fischer Cat #4366596
Taqman Universal PCR Master Mix Thermo Fischer Cat #4305719
Nanostring human v3 miRNA for 827 human miRNAs Nanostring CSO-MIR3-12
Deposited data
Nanostring miRNA data GEO GSE189610
Software and algorithms
R statistical programming language The R project https://r-project.org
Prism GraphPad https://graphpad.com
Other
StepOnePlus Real Time PCR System Thermofisher Cat #4376600
nCounter FLEX Analysis System – nCounter Prepstation Nanostring Inc NA
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Clinical study design and sample collection
The clinical recruitment and study design for cohort 1 has been reported elsewhere (Mann et al., 2020).
Briefly, individuals with COVID-19 were recruited from 3 hospitals in the Greater Manchester area,
Manchester University Foundation Trust (MFT), Salford Royal NHS Foundation Trust (SRFT) and Pennine
Acute NHS Trust (PAT) under the framework of the Manchester Allergy, Respiratory and Thoracic Surgery
(ManARTS) Biobank (study no M2020-88) for MFT or the Northern Care Alliance Research Collection
(NCARC) tissue biobank (study no. NCA-009) for SRFT and PAT. Ethics approval was obtained from the
North West-Haydock Research Ethics Committee for ManARTS (reference 15/NW/0409) and from the
Wales Research Ethics Committee 4 for NCARC (reference 18/WA/0368). Participants were admitted to
hospital between April and November 2020 (Tables S1–S4). Samples were collected as soon after admis-
sion as possible and at one- or two-day intervals thereafter (Table S4).
For cohort 2, the leftover blood cohort, individuals with COVID-19 were recruited at York District Hospital,
York and Scarborough NHS Trust between January and March 2020 (Table S10). Patients were recruited at
admission. Ethics approval was obtained from Yorkshire & The Humber - LeedsWest Research Ethics Com-
mittee (REC reference 19/YH/0394 with approved SA002 amendment of IRAS project 269597). Samples
were first used for complete blood counts and stored for 12-48 h at room temperature before released
for plasma isolation.
For both cohorts, clinical information was extracted from written/electronic medical records. Only patients
who tested positive for SARS-CoV-2 by reverse transcriptase polymerase chain reaction (RT-PCR) on naso-
pharyngeal/oropharyngeal swabs or sputum were included. Disease severity was scored based on degree
of respiratory failure (Mann et al., 2020), as below:
Mild: less than 3 L/min or less than 28% supplemental oxygen and managed in a ward.
Moderate: less than 10 L/min or less than 60% supplemental oxygen, managed in a ward environment;
chronic NIV or CPAP (at home) or acute NIV for individuals with COPD.
Severe: any of more than 10 L/min or less than 60% supplemental oxygen, or use of acute NIV, or managed
in ICU with invasive ventilation.Where severity of disease changed during admission, the highest disease
severity score was selected for classification.
METHODS DETAILS
Blood plasma isolation
For cohort 1, whole venous blood was collected in tubes containing EDTA (Starstedt) and diluted 1:1 with
PBS. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using
Ficoll-Paque Plus (GE Healthcare) and 50 mL SepMate tubes (STEMCELL technologies) according to the
manufacturer’s protocol. Blood plasma, at the top of the gradient was collected and stored at 80C until
usage. For cohort 2, whole blood was collected in tubes containing EDTA (Starstedt). Blood plasma was
collected by centrifugation (1500 g for 10 min at 4).
RNA extraction and miRNA profiling
For Nanostring analyses (Cohort 1), RNAwas extracted from 800 mL plasma the Norgen Plasma/Serum RNA
Purification Midi kit (Norgen, Cat #56100). A spike-in non-human miRNA (osa-miR-414) was added to each
sample (5 mL from a 200 pM per sample) for normalisation. For miRNA profiling we used the Nanostring
nCounter platform and the human v3 miRNA panel was used containing probes for 827 human miRNAs.
Extraction of raw reads and analysis of the individual datasets was carried out using the nSolver Analysis
Software. For each miRNA the mean plus one standard deviation of negative controls from all counts was
subtracted. A minimum value of 1 to all counts. All miRNAs which were expressed above this threshold in
fewer than 10% of samples were removed, leaving 280 miRNAs for further analysis. The spike-in count (osa-
miR414) was used to normalise miRNA counts. Differential expression analysis on these normalised values
was performed by performing Mann Whitney U test, followed by a false discovery rate correction using the
Benjamini Hochberg correction to generate adjusted p values.
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For cohort 2, RNA was extracted from 200 mL of undiluted plasma using the Norgen Plasma/Serum RNA
Purification Mini kit (Norgen, Cat #55000) after addition of the spike RNA at the same concentration as
above. Targeted analysis of 9 miRNAs was performed usingmiRNA Taqman assays (Cat #4427975). Reverse
transcription was performed using the Taqman MicroRNA Reverse Transcription Kit (Cat #4366596), by
multiplexing primers for all 10 miRNAs (9 miRNAs+spike) after 1 in 6 dilution and using 5 mL RNA as tem-
plate. Quantitative PCR was performed using a StepOnePlus Real Time PCR System (ThermoFisher) and
using Taqman Universal PCR Master Mix (Cat #4305719) and standard cycling conditions as per manufac-
turer’s instructions (Taqman miRNA assays).
Cytokine and chemokine profiling
With the exemption of GM-CSF, for cytokine and chemokine profiling bead-based multiplex flow cytom-
etry assays were used. Cytokines and chemokines levels were quantified from patients’ plasma fractions
using three sets of pre-defined LEGENDplex panels: Human Th-2 cytokine Panel version 2 (IL2, IL4, IL5,
IL6, IL9, IL10, IL13, IL17A, IL17F, IL22, IFNg and TNF), Proinflammatory chemokine Panel 1 (CCL2, CCL3,
CCL4, CCL11, CCL17 and CCL20; CXCL1, CXCL5, CXCL8, CXCL9, CXCL10 and CXCL11) plus a separate
CCL5 1-plex kit (BioLegend, San Diego, USA) according to manufacturer’s instructions. GM-CSF was de-
tected and quantified using a sandwich ABTS ELISA kit (PeproTech EC, Ltd, UK). Statistical significance
in differences in cytokine and chemokine expression between groups were assessed using Mann Whitney
U test, followed by Benjamini Hochberg correction to generate adjusted p values.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data integration and statistical methods
Partial least squares regression (PLSR) was performed using the R package ‘pls’ with the response variable
encoded as 1.0, 2.0 and 3.0 for mild, moderate and severe observations respectively. Leave-one-patient-
out (L-O-P-O) classification was carried out by assigning the class corresponding to the closest integer
to the output response. For each patient, a model was built without using the data for any of that patient’s
samples and the results are given for the prediction of the observations left out for each patient in turn. As
results showed mild and moderate patients could not be distinguished, the L-O-P-O classification was
repeated using just two classes, with mild and moderate observations combined as one class.
For correspondence analysis (CA), min-max scaling was applied to the data for each chemokine and cyto-
kine so that each variable had aminimumof zero andmaximum of 3.0 over all observations.With values less
than 1.0 considered as ‘low’, values between 1.0 and 2.0 as ‘medium’ and values >2.0 considered as ‘high’,
count data for each severity group was obtained for each variable. To reduce the number of variables, me-
dium counts were excluded from CA, which was performed using the corresp() function from the ‘MASS’
package in R. All count data was used in chi-squared tests to assess the significance of any association.
Balloon plots were created using only counts for either high values or low values with the function
ballonplot() from the R package ‘gplot’.
The R package ‘CCA’ was used for canonical correlation analysis (CCA) to find linear combinations of
chemokines and cytokines with maximal correlation to a linear combination of the up-regulated miRNAs
associated with cell death. To reduce the likelihood of overfitting, we only included cytokines and
chemokines with individual correlation to any of these miRNAs >0.4 in absolute value. We developed a
model using the 43 samples from 12 patients (chosen randomly from the 17 available observations) with
severe disease, using Wilks’ Lambda with Rao’s F-approximation to assess the significance of correlations.
We used the data for the remaining 5 severe patients as an independent test set.
For all correlations between individual variables, Spearman’s rank-order correlation was used. Where there
were missing values for clinical data, correlations were calculated over all patients for which values were
available. Heatmaps showing multiple correlations were created using the package ‘pheatmap’ in R with
thresholds for the minimum absolute values shown chosen to limit the size of the heatmaps.
Stepwise logistic regression was also carried out in R using the functions ‘glm’ and ‘step’. Models were
compared using the residual deviance (the lack of fit to the perfect model) and Akaike Information Criterion
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